Ebert, Nadja http://orcid.org/0000-0002-2361-6006
Kensche, Anna
Löck, Steffen
Hadiwikarta, Wahyu Wijaya
Hänsch, Anna
Dörr, Wolfgang
Krause, Mechthild
Hannig, Christian
Baumann, Michael
Article History
Received: 24 April 2020
Accepted: 24 August 2020
First Online: 24 September 2020
Compliance with ethical guidelines
:
: N. Ebert, A. Kensche, S. Löck, W.W. Hadiwikarta, A. Hänsch, W. Dörr, M. Krause, C. Hannig and M. Baumann received financial support from Naturprodukte Dr. Pandalis GmbH & Co. KG for this study. The funding had no influence on collection, analyses, and data evaluation. N. Ebert was co-principal investigator for funded research projects to the University of Dresden by Merck KGaA (2014–open). N. Ebert confirms that the above funding source was not involved in the design of this study, the preparation of this paper, the materials used, or the collection, analysis, and interpretation of data. M. Krause declares that within the past 5 years she received funding for her research projects and for educational grants to the University of Dresden IBA (2016), Merck KGaA (2016–2030), Medipan GmbH (2014–2018). As chair of OncoRay (Dresden) she signed/s contracts for her institute(s) and for the staff for research funding and collaborations with different companies. In the past 5 years, M. Baumann attended an advisory board meeting of MERCK KGaA (Darmstadt), for which the University of Dresden received a travel grant. He further received funding for his research projects and for educational grants to the University of Dresden by Teutopharma GmbH (2011–2015), IBA (2016), Bayer AG (2016–2018), Merck KGaA (2014–open), Medipan GmbH (2014–2018). He is on the supervisory board of HI-STEM gGmbH (Heidelberg) for the German Cancer Research Center (DKFZ, Heidelberg) and also member of the supervisory body of the Charité University Hospital, Berlin. As former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), he has been or is still responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide, including but not limited to pharmaceutical corporations like Bayer, Boehringer Ingelheim, Bosch, Roche and other corporations like Siemens, IBA, Varian, Elekta, Bruker and others. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including the DKFZ-PSMA617 related patent portfolio (WO2015055318 (A1), ANTIGEN (PSMA)) and similar intellectual propterty portfolios. Dr. Baumann confirms that to the best of his knowledge none of the above funding sources was involved in the preparation of this paper.
: The study was approved by the institutional ethics committee of the Technische Universität Dresden (EK 281082011). Only patients who met the inclusion criteria and signed a consent form were enrolled in the study and randomized to receive either Cystus® or sage tea.